Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Starbucks Corp (SBUX) Price & Performance

Cassava Sciences IncTrade
Starbucks CorpTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Starbucks Corp — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Starbucks Corp trades at $106.35 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 2546.4× Cassava Sciences Inc's market cap, and Starbucks Corp pays a 2.33% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNASBUX
Market Cap
$47.75M$121.59B
Sector
HealthConsumer Cyclical
52-Week High
$4.64$108.37
52-Week Low
$0.87$78.46
Enterprise Value
-$34.93M$140.42B
Volume
7,493,833
Dividend Yield
2.33%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Starbucks Corp

Starbucks (SBUX) trades at $104.65, down 0.88% on the day, with technical indicators neutral and support near $104. The company reported mixed quarterly EPS results, beating in Q1 and Q2 2026 but missing in Q4 2025, while raising its fiscal 2026 outlook. Revenue grew to $37.18B in 2025, but net income fell to $1.86B, compressing margins. Analyst consensus is a Buy with a $113.60 price target, citing a traffic recovery and cost initiatives.

The outlook hinges on sustaining sales momentum and margin expansion amid high valuation multiples. Risks include execution on turnaround plans, competitive pressure, and debt levels. Upside potential exists if earnings recovery continues, but investors face volatility from macroeconomic headwinds and premium pricing.

Returns comparison

Trailing returns across standard periods

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Starbucks Corp

Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.

Read more on SBUX